Commencement of INX-0125 Phase 1 Clinical Trial Triggers US$1.0 Million Milestone Payment to INEX
After INEX pays third-party obligations of approximately US$200,000, the Company will forward the remainder of the Hana milestone payment to former INEX noteholders as provided in an agreement with noteholders. This payment will reduce INEX's future contingent payments to the noteholders from US$24.4 million to US$23.6 million.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.